icone plus
Contact Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
Substantial actual benefit
Clinical Added Value
important
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation.
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
zjUUAst9dfvKx0RB
Listen
